Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) Earnings Dividend

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s revenue jumped 10.23% since last year same period to $1219900Mn in the Q2 2026. On a quarterly growth basis, Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has generated 9.44% jump in its revenue since last 3-months.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s net profit fell -8.89% since last year same period to $113197Mn in the Q2 2026. On a quarterly growth basis, Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has generated 557.07% jump in its net profits since last 3-months.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s net profit margin fell -17.35% since last year same period to 9.28% in the Q2 2026. On a quarterly growth basis, Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has generated 517.64% jump in its net profit margins since last 3-months.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s earning per share (EPS) estimates for the current year stand at 0.41.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s earning per share (EPS) fell -99.68% since last year same period to 0.48 in the Q2 2026. This indicates that the Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has generated -99.68% annual rate of fall in its earning per share (EPS) in the last 4 quarters.